Bain Capital Life Sciences raises $3B, largest fund to date

Bain Capital Life Sciences raises $3B, largest fund to date

Bain Capital Life Sciences, the life sciences investing arm of Bain Capital, has raised $3 billion for its third fund, the largest fund in its history. The fund will invest in innovative life sciences companies across all stages of development, including pre-revenue startups, clinical-stage companies, and commercial-stage businesses.

The fund will invest in a variety of life sciences companies, including those focused on:

• Therapeutics
• Diagnostics
• Medical devices
• Digital health

Bain Capital Life Sciences is a leading investor in the life sciences industry, with a track record of investing in successful companies such as Alnylam Pharmaceuticals, Moderna Therapeutics, and Guardant Health.

The fund will be led by Bain Capital Life Sciences' managing directors, including:

• Nabil Daoud
• Scott Boyer
• Erez Chimovits
• Zach Coelius
• Steve Pagliuca

Bain Capital Life Sciences has a team of experienced investment professionals with deep expertise in the life sciences industry. The team has a proven track record of identifying and investing in promising life sciences companies.

The fund will invest in companies across the globe, with a focus on North America and Europe.

Bain Capital Life Sciences has a global presence, with offices in Boston, New York, Menlo Park, London, and Munich. The team has a deep understanding of the global life sciences market and is well-positioned to identify and invest in promising companies around the world.

The fund will invest in companies that are developing innovative new therapies and technologies.

Bain Capital Life Sciences is committed to investing in companies that are developing innovative new therapies and technologies that have the potential to improve the lives of patients. The team has a strong track record of investing in companies that have developed successful new drugs, devices, and diagnostics.

The fund will invest in companies that have the potential to generate strong returns.

Bain Capital Life Sciences is a profit-driven organization, and the team is committed to investing in companies that have the potential to generate strong returns for investors. The team has a proven track record of identifying and investing in companies that have achieved significant financial success.